Asthma Epidemiology Overview and Insights 2015-2024 - ResearchAndMarkets.com

DUBLIN--()--The "Asthma: Epidemiology Overview and Insights" report has been added to ResearchAndMarkets.com's offering.

Asthma: Epidemiology Overview and Insights report delivers an in-depth understanding of the disease and the historical & forecasted epidemiology of Asthma disease in terms of diagnosed prevalent and the treated patients in the US, EU5 (Germany, France, Italy, Spain, UK), and Japan market till 2024. The epidemiology numbers in the report have been derived based on numerous studies, survey reports and views of key opinion leaders.

Disease Indication Overview:

This section of the report gives the overview of Asthma disease indication in detail. The section highlights the basic definition, causes and symptoms of disease and further details the types of Asthma disease. Further details on the profile of Asthma patients, Symptoms experienced by the patients, and disease progression in patients are outlined in the report. The report further highlights the multiple methods through which the patient can be diagnosed for Asthma disease.

Epidemiology Forecasts to 2024:

This section of the report provides the overview of Asthma diagnosed prevalent and treated patients in the US, EU5 (Germany, France, Italy, Spain and UK) and Japan market year wise starting from 2015 till 2024. The epidemiology numbers in the report have been derived based on numerous studies, survey reports and views of key opinion leaders.

Companies Mentioned

  • Mitsubishi Tanabe Pharma
  • Menarini
  • GlaxoSmithKline
  • Dong-A ST
  • Dong-A Socio Holdings
  • Hanmi Pharmaceutical
  • Abdi Ibrahim
  • Novartis
  • Roche
  • Daiichi Sankyo
  • PDL BioPharma
  • Tanox
  • Cipla
  • Merck & Co
  • Astellas Pharma
  • AstraZeneca
  • Esteve
  • Daewoong Pharmaceutical
  • Elan
  • SkyePharma
  • Innoviva
  • Vectura
  • Schering-Plough
  • Teva Pharmaceutical Industries
  • UCB
  • Kyowa Hakko Kirin
  • MedImmune
  • Lonza
  • GC Pharma
  • PARI Medical Holding
  • Boehringer Ingelheim
  • Pfizer
  • Sanofi
  • Sosei
  • Pearl Therapeutics

For more information about this report visit https://www.researchandmarkets.com/research/lbbfpb/asthma?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Asthma Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Asthma Drugs